Dermira, Inc (DERM) saw its loss widen to $29.51 million, or $0.79 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $28.44 million, or $0.95 a share. Revenues for the quarter were $1.07 million. The company has not recorded any revenues for the previous year period.
Operating loss for the quarter was $30.12 million, compared with an operating loss of $28.76 million in the previous year period.
“We are off to a great start in 2017, including the successful completion of our third Phase 3 clinical trial for CIMZIA, a pre-NDA meeting with the FDA for glycopyrronium tosylate and the closing of a successful follow-on offering,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we prepare for the remainder of the year, we anticipate UCB submitting marketing applications for CIMZIA for the treatment of chronic plaque psoriasis in the United States, Europe and Canada in the third quarter and we expect to submit a new drug application for glycopyrronium tosylate for the treatment of axillary hyperhidrosis in the second half of this year. We also continue to work on expanding our product portfolio and have made progress on building our commercial operations, which we plan to provide an update on later in the year.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]